A New Way Forward
for Autoimmune Disease
CEO Fireside
Changing What’s Possible in Autoimmune Treatment
Nkarta CEO Paul Hastings, a lifelong patient advocate, breaks down natural killer cell therapy and how it could potentially transform the therapeutic landscape in autoimmunity.
Patients First
Our Clinical Trial Promise
Instead of asking people with serious diseases to reconstruct their lives around our studies, drug developers should be striving to design our research around their lives. Read about what we’re doing to make clinical trial opportunities more accessible and equitable.
Nature
Boosted Killer Cells Show Promise For Autoimmune Disease
“Supercharged ‘natural killer’ cells could become a potent way to reset a disordered immune system,” according to one of the world's most prestigious scientific journals.
Our Autoimmune Targets
We are dedicated to realizing the potential of natural killer (NK) cells for the treatment of autoimmune diseases. Our proprietary technology is designed to harness the inherent disease-fighting capabilities of these immune cells to act against cells that are dysfunctional, diseased or otherwise abnormal.
Follow us on Linkedin
More than a dozen NKredible Nkartans (and our family members) spent a gorgeous Sunday morning last weekend at the San Francisco Walk to End Lupus Now. We heard so many powerful stories from #lupus warriors, family members and care partners. We heard from a 70-year-old mother who lost both of her daughters to this disease. She shared her family's unbearable grief and their determination to make a difference for other families in the hope that, together, we might spare others from such unbearable loss. We heard from a young woman adorned in butterflies battling SLE, whose hands trembled as she took our pamphlets and icepacks and thanked us for working in this space in an effort to bring new treatment options to the fore.
Nkarta continues our work in the clinic in our Ntrust-1 #clinicaltrial, redoubled in our commitment to explore the potential of NK #celltherapy to change the standard of care in the fight against lupus and other B cell-mediated #autoimmune diseases.
